Bookmarks
Prediction of significant bleeding during anticoagulant use in patients with cancer-related venous thromboembolism: an English cohort study.
Safe People
Bristol-Myers Squibb Pharmaceuticals Ltd (BMS)
Commercial
Ayman Nassar - Chief Investigator - Bristol Myers Squibb - Europe ( BMS )Carlos Martinez - Corresponding Applicant - Institute for EpidemiologyStatistics and Informatics GmbH (Pharma Epi)Alexander Cohen - Collaborator - King's College LondonChristopher Wallenhorst - Collaborator - Institute for EpidemiologyStatistics and Informatics GmbH (Pharma Epi)Raza Alikhan - Collaborator - University Hospital of WalesSarah Grundy - Collaborator - Bristol Myers Squibb - Europe ( BMS )Satarupa Choudhuri - Collaborator - Not from an OrganisationStephan Rietbrock - Collaborator - Institute for EpidemiologyStatistics and Informatics GmbH (Pharma Epi)
Safe Projects
CPRD878
Blood clots often form in the veins of the legs or in the lungs and are more common in patients with cancer. The risk is highest following the diagnosis or treatment of the cancer with drugs, radiation or surgery. Blood clots are usually treated with “blood thinning” drugs called anticoagulants. Guidelines recommend treatment for 3-6 months for some patients with longer courses of therapy often recommended for patients with cancer and clots. Whilst taking anticoagulants patients are more likely to have bleeding complications and patients with cancer are more likely to bleed than those without cancer.
This observational cohort study aims to investigate predictors for the risk of significant bleeding during anticoagulant (AC) treatment for active cancer associated venous thromboembolism (CAT).
29/01/2021
Safe Data
HES Admitted Patient Care
HES Outpatient
ONS Death Registration Data
Patient Level Index of Multiple Deprivation
Safe Setting
Release